+Search query
-Structure paper
Title | Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. |
---|---|
Journal, issue, pages | PLoS Pathog, Vol. 16, Issue 12, Page e1009169, Year 2020 |
Publish date | Dec 28, 2020 |
Authors | Michela Perotti / Jessica Marcandalli / Davide Demurtas / Federica Sallusto / Laurent Perez / |
PubMed Abstract | Human cytomegalovirus (HCMV) is the primary viral cause of congenital birth defects and causes significant morbidity and mortality in immune-suppressed transplant recipients. Despite considerable ...Human cytomegalovirus (HCMV) is the primary viral cause of congenital birth defects and causes significant morbidity and mortality in immune-suppressed transplant recipients. Despite considerable efforts in vaccine development, HCMV infection still represents an unmet clinical need. In recent phase II trials, a MF59-adjuvanted gB vaccine showed only modest efficacy in preventing infection. These findings might be attributed to low level of antibodies (Abs) with a neutralizing activity induced by this vaccine. Here, we analyzed the immunogenicity of each gB antigenic domain (AD) and demonstrated that domain I of gB (AD5) is the main target of HCMV neutralizing antibodies. Furthermore, we designed, characterized and evaluated immunogenic responses to two different nanoparticles displaying a trimeric AD5 antigen. We showed that mice immunization with nanoparticles induces sera neutralization titers up to 100-fold higher compared to those obtained with the gB extracellular domain (gBECD). Collectively, these results illustrate with a medically relevant example the advantages of using a general approach combining antigen discovery, protein engineering and scaffold presentation for modern development of subunit vaccines against complex pathogens. |
External links | PLoS Pathog / PubMed:33370407 / PubMed Central |
Methods | EM (single particle) |
Resolution | 19.0 - 20.0 Å |
Structure data | EMDB-11398: EMDB-11400: |
Source |
|